DMW – Klinischer Fortschritt, Table of Contents Dtsch Med Wochenschr 2015; 140(12): 882-884DOI: 10.1055/s-0041-102418 Klinischer Fortschritt Hämatologie und Onkologie © Georg Thieme Verlag KG Stuttgart · New York Haarzell-Leukämie Hairy Cell Leukemia Sascha Dietrich 1 Medizinische Klinik V, Universitätsklinikum Heidelberg, Heidelberg 2 Abteilung Translationale Onkologie, Nationales Centrum für Tumorerkrankungen (NCT) und Deutsches Krebsforschungszentrum (dkfz), Heidelberg 3 EMBL Heidelberg, Heidelberg, Germany , Thorsten Zenz 2 Abteilung Translationale Onkologie, Nationales Centrum für Tumorerkrankungen (NCT) und Deutsches Krebsforschungszentrum (dkfz), Heidelberg 3 EMBL Heidelberg, Heidelberg, Germany › Author Affiliations Recommend Article Abstract Buy Article Schlüsselwörter SchlüsselwörterHaarzellenleukämie - BRAF-V600E-Mutation - B-Zell-Neoplasie Keywords Keywordshairy cell leukemia - braf v600e mutation - B-cell neoplasm Full Text References Literatur 1 Grever M, Kopecky K, Foucar MK et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol 1995; 13: 974-982 2 Saven A, Burian C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998; 92: 1918-1926 3 Else M, Dearden CE, Matutes E et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 2009; 145: 733-740 4 Tiacci E, Trifonov V, Schiavoni G et al. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011; 364: 2305-2315 5 Samuel J, Macip S, Dyer MJ. Efficacy of vemurafenib in hairy-cell leukemia. N Engl J Med 2014; 370: 286-288 6 Chung SS, Kim E, Park JH et al. Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia. Sci Transl Med 2014; 6: 238ra71 7 Waterfall JJ, Arons E, Walker RL et al. High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias. Nat Genet 2014; 46: 8-10 8 Dietrich S, Glimm H, Andrulis M, von Kalle C et al. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med 2012; 366: 2038-2040 9 Follows GA, Sims H, Bloxham DM et al. Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib. Br J Haematol 2013; 161: 150-153 10 Peyrade F, Re D, Ginet C et al. Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation. Haematologica 2013; 98: e20-2 11 Tiacci E, Falini B. Efficacy and Safety of the BRAF Inhibitor Vemurafenib in Hairy Cell Leukemia Patients Refractory to or Relapsed after Purine Analogs: A Phase-2 Italian Clinical Trial. Milan: EHA; 2014 12 Park J, Chung S, Chung Y et al. Phase II Trial Of The BRAF Inhibitor, Vemurafenib, In Patients With BRAF Mutant Relapsed Or Refractory Hairy Cell Leukemia. New Orleans: ASH; 2013 13 Dooley AJ, Gupta A, Bhattacharyya M, Middleton MR. Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series. Ther Adv Med Oncol 2014; 6: 262-266 14 Dietrich S, Pircher A, Andrulis A et al. BRAF Inhibition in Hairy Cell Leukemia: Multicentre Experience of 21 Patients Treated with Vemurafenib. San Francisco: ASH; 2014 15 Robert C, Karaszewska B, Schachter J et al. Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. N Engl J Med 2014; 372: 30-39 16 Kreitman RJ, Tallman MS, Robak T et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol 2012; 30: 1822-1828
